Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Toxicol Appl Pharmacol. 2014 Jun 24;279(2):220–229. doi: 10.1016/j.taap.2014.06.010

Figure 2. I.P. or I.V. treatment with MMP-activated PrAg-L1 + LF caused reduced GI motility.

Figure 2

3 doses of PBS (black) or PrAg-L1 + LF (green) were administered either intraperitoneally (A) or intravenously (B). At both the I.P. and I.V. MTD6s, no physical evidence of GI abnormalities was anticipated, while at doses of 2XMTD6 GI histopathology was expected. P-values were determined using a Student’s T-test, two-tailed.